Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.

被引：0
|
作者：
Gide, Tuba Nur
Quek, Camelia
Madore, Jason
Menzies, Alexander M.
Dent, Rebecca
Carlino, Matteo S.
Guminski, Alex
Saw, Robyn
Thompson, John F.
Wilmott, James S.
Scolyer, Richard A.
Long, Georgina V.
机构：
[1] Univ Sydney, Melanoma Inst Australia, Cent Clin Sch, Fac Med, Sydney, NSW, Australia
[2] Melanoma Inst Australia, Sydney, NSW, Australia
[3] Univ Sydney, Melanoma Inst Australia, Royal North Shore Hosp, North Sydney, Australia
[4] Westmead Hosp, Melanoma Inst Australia, Crown Princess Mary Canc Ctr, Sydney, NSW, Australia
[5] Blacktown Hosp, Sydney, NSW, Australia
[6] Univ Sydney, Royal North Shore Hosp, Melanoma Inst Australia, Sydney, NSW, Australia
[7] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[8] Univ Sydney, Melanoma Inst Australia, Royal Prince Alfred Hosp, Sydney, NSW, Australia
[9] Univ Sydney, Melanoma Inst Australia, Sydney Med Sch, Discipline Pathol, Sydney, NSW, Australia
[10] Univ Sydney, Melanoma Inst Australia, Mater Hosp, Royal North Shore Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 07期
关键词：
D O I：
10.1200/JCO.2017.35.7_suppl.51
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
51
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Experimental bladder cancer is eradicated by combined administration of CpG with anti-CTLA-4 or anti-PD-1, but not with anti-PD-L1
    Mangsbo, Sara
    Sadeghi, Arian
    Korman, Alan
    Loskog, Angelica
    Totterman, Thomas
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2008, 68 (02) : 212 - 212
  • [42] Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
    Xiang, Ze
    Li, Jiayuan
    Zhang, Zhengyu
    Cen, Chao
    Chen, Wei
    Jiang, Bin
    Meng, Yiling
    Wang, Ying
    Berglund, Bjoern
    Zhai, Guanghua
    Wu, Jian
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [43] Opportunistic autoimmune disorcers potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1
    Kong, Yi-chi M.
    Flynn, Jeffrey C.
    FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [44] Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
    Gordon, Ilyssa O.
    Wade, Takisha
    Chin, Kevin
    Dickstein, Jerome
    Gajewski, Thomas F.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (08) : 1351 - 1353
  • [45] Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
    Ilyssa O. Gordon
    Takisha Wade
    Kevin Chin
    Jerome Dickstein
    Thomas F. Gajewski
    Cancer Immunology, Immunotherapy, 2009, 58 : 1351 - 1353
  • [46] Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study
    Umeda, Yoshiyasu
    Yoshikawa, Shusuke
    Kiniwa, Yukiko
    Maekawa, Takeo
    Yamasaki, Osamu
    Isei, Taiki
    Matsushita, Shigeto
    Nomura, Motoo
    Nakai, Yasuo
    Fukushima, Satoshi
    Saito, Shintaro
    Takenouchi, Tatsuya
    Tanaka, Ryo
    Kato, Hiroshi
    Otsuka, Atsushi
    Matsuya, Taisuke
    Baba, Natsuki
    Nagase, Kotaro
    Inozume, Takashi
    Onuma, Takehiro
    Kuwatsuka, Yutaka
    Fujimoto, Noriki
    Kaneko, Takahide
    Onishi, Masazumi
    Namikawa, Kenjiro
    Yamazaki, Naoya
    Nakamura, Yasuhiro
    EUROPEAN JOURNAL OF CANCER, 2021, 157 : 361 - 372
  • [47] Abscopal Effect in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors (Anti-CTLA-4 and Anti-PD1): A Retrospective Analysis of a Single Institution
    Carvalho, R. F.
    Ferrigno, R.
    Marotta, R. C.
    Amarantes, M. P. F.
    Schmerling, R. A.
    Haddad, C. K.
    Gil, E.
    Moraes, P. L.
    Zanuncio, P. H.
    Buzaid, A. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S159 - S159
  • [48] Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
    Lipson, Evan J.
    Drake, Charles G.
    CLINICAL CANCER RESEARCH, 2011, 17 (22) : 6958 - 6962
  • [49] Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4+Anti-PD-1 Therapy
    Buchbinder, Elizabeth. I. I.
    Pfaff, Kathleen. L. L.
    Turner, Madison. M. M.
    Manos, Michael
    Ouyang, Olivia
    Ott, Patrick. A. A.
    Giobbie-Hurder, Anita
    Rodig, Scott. J. J.
    Hodi, F. Stephen
    JOURNAL OF IMMUNOTHERAPY, 2023, 46 (05) : 192 - 196
  • [50] Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma
    Campbell, Katie M.
    Amouzgar, Meelad
    Pfeiffer, Shannon M.
    Howes, Timothy R.
    Medina, Egmidio
    Travers, Michael
    Steiner, Gabriela
    Weber, Jeffrey S.
    Wolchok, Jedd D.
    Larkin, James
    Hodi, F. Stephen
    Boffo, Silvia
    Salvador, Lisa
    Tenney, Daniel
    Tang, Tracy
    Thompson, Marshall A.
    Spencer, Christine N.
    Wells, Daniel K.
    Ribas, Antoni
    CANCER CELL, 2023, 41 (04) : 791 - +
12345